Maternal Use of Drugs for Intestinal Problems, Except Intestinal Inflammations, and Infant Congenital Malformations

  • Bengt Källén


Rather low but statistically significant malformation risk increases were seen after maternal use of drugs for functional intestinal diseases and for anti-propulsive drugs. These effects may be explained by a confounding by indication, perhaps as a result of nutritional disturbances.


  1. Czeizel AE, Kazy Z, Puhó E. A population-based case-control teratological study of oral nystatin treatment during pregnancy. Scand J Infect Dis. 2003;35:830–5.CrossRefGoogle Scholar
  2. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs during pregnancy. Littttleton, MA: Publishing Sciences Group Inc.; 1977.Google Scholar
  3. Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, Koren G. Prospective, controlled, multicenter study of loperamide in pregnancy. Can J Gastroenterol. 2000;14:185–7.CrossRefGoogle Scholar
  4. Källén B. Congenital malformations in the offspring when drugs for functional gastrointestinal disease were used during early pregnancy. Intern Med. 2014;S1:004. Scholar
  5. Källén B, Nilsson E, Otterblad Olausson P. Maternal use of loperamide in early pregnancy and delivery outcome. Acta Paediatr. 2008;97:541–5.CrossRefGoogle Scholar
  6. Schwethelm B, Margulis LH, Miller C, Smith S. Risk status and pregnancy outcome among Medicaid recipients. Am J Prev Med. 1989;5:157–63.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bengt Källén
    • 1
  1. 1.Tornblad Institute for Comparative EmbryologyLund UniversityLundSweden

Personalised recommendations